Literature DB >> 6394616

Multicenter evaluation of a 1-h enzyme-linked immunosorbent assay for rubella serology.

W L Boteler, K J Barnes, E Buimovici-Klein, A J O'Beirne.   

Abstract

A 1-h enzyme-linked immunosorbent assay (Rubestat) was developed for rubella virus immunoglobulin G detection. The assay used phenolphthalein monophosphate as the substrate, which, when developed, can easily be read visually. Rubestat compared very favorably to hemagglutination inhibition and commercial enzyme-linked immunosorbent assays in its ability to determine immune status. Rubestat demonstrated greater than 97% specificity, sensitivity, and accuracy as compared with other methodologies at 10 different laboratories. The Rubestat index values were precise, with coefficients of variation for intra- and interassay variation of less than 10%. Mean index values had a linear correlation with hemagglutination inhibition titers (r2 greater than 0.97). A population distribution of index values illustrated two distinct bell-shaped curves representing the positive and negative populations. Studies of acute and convalescent serum pairs showed Rubestat to be as accurate as hemagglutination inhibition in determining seroconversion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6394616      PMCID: PMC271534          DOI: 10.1128/jcm.20.6.1140-1144.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  RUBELLA COMPLEMENT FIXATION TEST.

Authors:  J L SEVER; R J HUEBNER; G A CASTELLANO; P S SARMA; A FABIYI; G M SCHIFF; C L CUSUMANO
Journal:  Science       Date:  1965-04-16       Impact factor: 47.728

2.  Recovery of rubella virus from army recruits.

Authors:  P D PARKMAN; E L BUESCHER; M S ARTENSTEIN
Journal:  Proc Soc Exp Biol Med       Date:  1962-10

3.  Comparison of an enzyme-linked immunosorbent assay with indirect hemagglutination and hemagglutination inhibition for determination of rubella virus antibody: evaluation of immune status with commercial reagents in a clinical laboratory.

Authors:  A L Truant; B L Barksdale; T W Huber; L B Elliott
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

4.  Improved serological diagnosis of rubella.

Authors:  N E Cremer; S J Hagens; R Fukuchi
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

5.  Detection of rubella antibodies by hemagglutination inhibition, indirect fluorescent-antibody test, and enzyme-linked immunosorbent assay.

Authors:  M V Zartarian; G Friedly; E M Peterson; L M de la Maza
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

6.  Low level rubella immunity detected by ELISA and specific lymphocyte transformation.

Authors:  E Buimovici-Klein; A J O'Beirne; S J Millian; L Z Cooper
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

7.  Rubella antibodies detected by several commercial immunoassays in hemagglutination inhibition-negative sera.

Authors:  K T Kleeman; D J Kiefer; S P Halbert
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

8.  Enzyme-linked immunosorbent assay for detection of measles antibody.

Authors:  W L Boteler; P M Luipersbeck; D A Fuccillo; A J O'Beirne
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

9.  RUBELLA ANTIBODIES IN HUMAN SERUM: DETECTION BY THE INDIRECT FLUORESCENT ANTIBODY TECHNIC.

Authors:  G C BROWN; H F MAASSAB; J A VERONELLI; T J FRANCIS
Journal:  Science       Date:  1964-08-28       Impact factor: 47.728

10.  Evaluation of solid-phase enzyme-immunoassay procedure in immunity surveys and diagnosis of rubella.

Authors:  A Vaheri; E M Salonen
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

View more
  2 in total

1.  Measles in a west African nomadic community.

Authors:  L Loutan; S Paillard
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

2.  Evaluation of rubella immune status by three commercial enzyme-linked immunosorbent assays.

Authors:  P R Field; D W Ho; A L Cunningham
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.